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Introduction: Bipolar disorder requires long-term
treatment but non-adherence is a common problem.
Antipsychotic long-acting injections (LAIs) have been
suggested to improve adherence but none are licensed
in the UK for bipolar. However, the use of second-
generation antipsychotics (SGA) LAIs in bipolar is not
uncommon albeit there is a lack of systematic review in
this area. This study aims to systematically review
safety and efficacy of SGA LAIs in the maintenance
treatment of bipolar disorder.
Methods and analysis: The protocol is based on
Preferred Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA) and will include only
randomised controlled trials comparing SGA LAIs in
bipolar. PubMed, EMBASE, CINAHL, Cochrane Library
(CENTRAL), PsychINFO, LiLACS, http://www.
clinicaltrials.gov will be searched, with no language
restriction, from 2000 to January 2016 as first SGA
LAIs came to the market after 2000. Manufacturers of
SGA LAIs will also be contacted. Primary efficacy
outcome is relapse rate or delayed time to relapse or
reduction in hospitalisation and primary safety
outcomes are drop-out rates, all-cause discontinuation
and discontinuation due to adverse events. Qualitative
reporting of evidence will be based on 21 items listed
on standards for reporting qualitative research (SRQR)
focusing on study quality (assessed using the Jadad
score, allocation concealment and data analysis), risk
of bias and effect size. Publication bias will be
assessed using funnel plots. If sufficient data are
available meta-analysis will be performed with primary
effect size as relative risk presented with 95% CI.
Sensitivity analysis, conditional on number of studies
and sample size, will be carried out on manic versus
depressive symptoms and monotherapy versus
adjunctive therapy.
Ethics and dissemination: Ethical approval is not
required as primary data will not be collected. The
results will be disseminated through a peer-reviewed
publication, conference presentation and the press.
Study registration number: PROSPERO
CRD42015023948.
BACKGROUND
The lifetime prevalence of bipolar I disorder
is estimated at 1% of the adult population,
and bipolar II disorder affects approximately
0.4% of adults.1 Bipolar disorder, featuring
mood and activity level disturbance, is a recur-
rent disorder; it usually requires long-term
maintenance therapy to prevent future mood
episodes—the primary goal of treatment.2
Lithium remains the gold standard prophylac-
tic treatment for bipolar disorder.1 However,
lithium may not be suitable for all patients
due to a lack of response or adverse events, or
patients may not accept lithium due to
various reasons including monitoring require-
ment and/or side effects.3 Thus, many
patients require alternative prophylactic treat-
ment for bipolar disorder. Many guidelines
Strengths and limitations of this study
▪ This systematic review will search a comprehen-
sive list of databases using well-defined search
strategy; will contact manufacturers for any
unpublished and/or ongoing trials.
▪ This study will clarify the position of second-
generation antipsychotics (SGAs) long-acting
injections (LAIs) in maintenance treatment of
bipolar disorder.
▪ Qualitative evidence summary and meta-analysis
will address some highly relevant clinical ques-
tions in bipolar disorder. Subgroup analyses will
further enhance the applicability of the results
from this study.
▪ This review is focused on as SGA LAIs since
first generation antipsychotics are not considered
preferred choice in maintenance treatment of
bipolar disorder due to risk of induction of
depression.
▪ Lack of data and significant heterogeneity may
prevent meta-analysis.
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including British Association of Psychopharmacology,4
The World Federation of Societies of Biological
Psychiatry (WFSBP),5 Canadian Network for Mood and
Anxiety Treatments (CANMAT) and International
Society for Bipolar Disorders (ISBD),6 and National
Institute for Health and Care Excellence (NICE)1 from
the UK recommend some second-generation anti-
psychotic (SGA, also known as atypical antipsychotics) as
a long-term treatment option for bipolar disorder; and
many oral SGAs are licensed in the UK for this
indication.7
Non-adherence to the prescribed treatment is a major
problem and common in bipolar disorder. Estimated fre-
quency of non-adherence in bipolar range between 10%
and 60% (median 40%).8 Non-adherence increases the
risk of relapse and suicide;9 and increased risk of rehos-
pitalisation.8 LAIs, also known as depots have some clear
advantages due to assurance that medication will be
administered and the opportunity for healthcare profes-
sionals to step in immediately if patients stop treat-
ment.10 Evidence from studies in people with
schizophrenia suggests antipsychotics LAIs reduce
relapses, reduce medication discontinuation rates and
improve outcomes compared to oral antipsychotics
although some Cochrane reviews of various depots did
not find any convincing difference.10 However, these
Cochrane reviews also included inpatient studies, short-
term trials of just a few weeks duration10 and mostly
included only first-generation antipsychotic (FGA, also
known as typical antipsychotics) LAIs. LAIs formulations
have other pharmacological advantages: more predict-
able bioavailability since LAIs medications bypass gastro-
intestinal absorption and the effect of first-pass hepatic
metabolism, more stable plasma levels compared to oral
antipsychotics, sustained plasma levels of medication at
therapeutic range.8
The use of SGA LAIs in the maintenance treatment of
bipolar disorder has ignited interest for improving adher-
ence and reducing the risk of relapse.8 Over the past
5 years two new SGA LAIs, aripiprazole and paliperidone,
have been introduced in the UK. None of the SGA LAIs
are currently licensed for bipolar disorder in the UK7
albeit clinical experience suggests their uses for this indi-
cation are not infrequent. Recent (2011) mixed-
treatment meta-analysis suggests that antipsychotics are
more effective than mood stabilisers in the treatment of
mania.11 Some studies have found that risperidone LAI is
effective for maintenance treatment in bipolar disorder7 8
and CANMAT recommends risperidone LAI as one of
the first-line treatment options in maintenance treatment
of bipolar disorder.6 Risperidone LAI is approved by US
Food and Drug Administration for monotherapy or as an
adjunctive therapy to lithium or valproate for the main-
tenance treatment of bipolar I disorder.12
Despite these potential advantages of antipsychotic
LAIs in the treatment of bipolar disorder there is a lack
of any properly conducted systematic review. During a
scoping search two literature reviews8 9 conducted
within past 5 years were identified. Literature reviews
offer a useful overview of the subject; however they gen-
erally lack the rigour of systematic reviews. Systematic
reviews of well-designed randomised controlled trials
(RCTs) are considered gold standard and top of the evi-
dence hierarchy in healthcare research.13–15 A systematic
review with a focused clinical question with clear
specifications searches all relevant databases with prede-
fined systematic search strategy and using prespecified
eligibility criteria for studies to be included. A systematic
review also provides the assessment of the quality of the
studies included in the review aiming to avoid bias
and therefore support evidence-based practice. With
predefined protocol good systematic reviews provide
robust evidence to support or change clinical practice.
Gigante et al8 reviewed evidence of FGAs and SGA
LAIs in bipolar disorder searching PubMed from 1950
to 2011 and published in English. This review included
all types of studies from RCTs to retrospective chart
reviews in their evidence synthesis. In terms of SGA LAIs
only literatures pertaining to risperidone LAI were
found. The level of evidence is limited due to small
number (n=2) of large RCTs. No RCTs were found
involving other SGA LAIs except risperidone. The
authors concluded that FGA LAI should not be a first
choice due to risk of induction of depression but sug-
gested risperidone LAI is effective in bipolar. This is con-
sistent with earlier literature review by Bond et al.16
Recently Samalin et al9 carried out another review of
SGA LAIs in bipolar disorder and concluded that risperi-
done LAI may be considered for maintenance treatment
of bipolar disorder but more evidence is required. This
review included RCTs, case series and did not include
any specific inclusion/exclusion criteria; did not
perform quality assessment; focused the search on
PubMed and EMBASE; and no information sought from
manufacturers. The authors carried out last search in
April 2013 which gives us around 2½ years of potential
extra literature, a good time frame to review evidence in
this moving field. In addition, Samalin et al found
studies only on risperidone LAI and this systematic
review is expected to find studies related to other SGA
as scoping exercise found some ongoing active studies of
other SGA LAI.
Chou et al17 authored an article titled “A Systemic
Review and Experts’ Consensus for Long-acting
Injectable Antipsychotics in Bipolar Disorder”. This was
an expert consensus building study and good endeavour
for consensus report on the topic but lacking any details
on review process and methodology, a critical and essen-
tial aspect of any systematic reviews. In addition, Chou
et al looked at both FGAs and SGAs and found studies
pertaining to risperidone LAI only in terms of SGA
LAIs.
This systematic review will:
▸ Include only RCTs comparing SGA LAIs with placebo
or other antipsychotics or mood stabilisers or treat-
ment as usual;
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▸ Search many other relevant databases as listed in the
methodology section;
▸ Contact manufacturers for further trials (both
ongoing and unpublished trials);
▸ Quality assess all included studies;
▸ Investigate the risk of bias.
The protocol is registered with PROSPERO—http://
www.crd.york.ac.uk/PROSPERO/—international pro-
spective register of systematic reviews.
The result of this study will have an impact on clinical
practice and prescribing decision either to support or dis-
courage use of SGA LAIs in maintenance treatment of
bipolar disorder. It is author’s intention to publish the
result of this study in a peer reviewed journal and to
widely communicate with key clinical and academic stake-
holders both nationally and internationally. The result
from the study will close the evidence gap and thus
inform healthcare professionals and patients of the evi-
dence or lack of it in using SGA LAIs in bipolar disorder.
OBJECTIVE
To conduct systematic review and meta-analysis of RCTs
evaluating efficacy and safety of SGA LAIs in mainten-
ance treatment of bipolar disorder.
METHODOLOGY
The research protocol is based on Preferred Reporting
Items for Systematic reviews and Meta-Analyses
(PRISMA).18 Specific Participants, Interventions,
Comparators, Outcomes and Study design; detailed
below will be used for study selection criteria:
1. Inclusion criteria:
Any studies not meeting following inclusion criteria
will be excluded.
A. Participants: patients of any age or sex with bipolar
disorder using any validated diagnostic system, for
example, Diagnostic and Statistical Manual of Mental
Disorders (DSM-V: 296) or the International
Classification of Diseases (ICD 10: F31).
B. Interventions: SGA LAIs in bipolar disorder.
C. Comparators: placebo, other antipsychotics, mood
stabiliser or treatment as usual.
D. Outcome measures:
▸ Primary efficacy outcome—relapse rate or delayed
time to relapse or reduction in hospitalisation
▸ Primary safety outcome—drop-out rates or all-cause
discontinuation or discontinuation due to adverse
events
▸ Secondary outcomes may include changes in BDRS
(Bipolar Disorder Rating Scale) or YMRS (Young
Mania Rating Scales), discontinuation due to hospi-
talisation and non-adherence (study defined),
safety outcome of SGA LAIs for example, EPSEs
and metabolic adverse effect—weight gain, hyper-
glycaemia, dyslipidaemia, hyperprolactinaemia.
E. Study design: RCTs with or without double blinding
with minimum duration of 6 months. It is anticipated
that most studies will be outpatient as non-adherence
in inpatients is unlikely due to staff administration.
Nonetheless this study will include both outpatients
and inpatients as some units are long stay inpatient
units in secure services or rehabilitation units and
since sustained therapeutic plasma level has been
suggested as a pharmacological advantage of LAIs in
addition to improvement in adherence.
Data sources, search strategy and study selection
Missing any relevant and significant study may render
the systematic review less credible. The following
detailed search strategy will be employed to ensure all
relevant studies are captured, independently analysed,
verified and quality assessed.
A comprehensive, electronic search strategy will be
used to identify relevant RCTs in humans where SGA
LAIs are being assessed for efficacy and safety in bipolar
disorder. There will be no language restrictions. Studies
published between January 2000 and Jan 2016 will be
searched since SGA LAIs came to the market only after
2000. The searches will be re-run just before the final
analyses and any further eligible studies retrieved for
inclusion.
Following databases will be searched: PubMed,
EMBASE, CINAHL, Cochrane Library (CENTRAL),
PsychINFO, LiLACS, http://www.clinicaltrials.gov. Any
relevant studies mentioned in those identified studies
will be searched manually, for example scoping the
references listed. Manufacturers of SGA LAIs will be
contacted for any ongoing or unpublished studies.
To capture all relevant studies the search strategy will
consist of three domains: disease (bipolar disorder),
treatment (SGA) and formulation (LAIs). Each domains
will be searched using many terms (as listed below) with
Boolean search operator “OR”. The Boolean search
operator “AND” will be used to connect these three
domains.
A. Disease domain: bipolar*, mood disorder*, mania*,
manic-depression*, hypomania*, AND
B. Treatment domain: antipsychotic*, neuroleptic*, psy-
chotropic*, atypical*, second generation anti-
psychotic*, SGA*, aripiprazole, olanzapine,
paliperidone, risperidone, ziprasidone AND
C. Formulation domain: depot*, long-acting injection*,
LAI*, prolonged release injection*, sustained release
injection*
The process; of identifying, screening of studies and
inclusion or exclusion of those studies; is shown in the
PRISMA flow diagram (figure 1) below.
Data collection, analysis and quality assessment
A list will be created for all identified studies from all
the resources searched. Any other studies mentioned or
referred to in these studies which seem relevant to the
review will be manually searched. Titles of all the studies
retrieved using the search strategy and those from add-
itional sources will be screened for their relevance to
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the review. Definite non-relevant studies will be excluded
while relevant, ambiguous or unclear studies will be
included for screening abstract.
All the articles will be screened for its title to check
their relevance by lead author (AP) and second reviewer
( JW). Abstracts of the remaining studies, after discard-
ing definite irrelevant studies, will be screened by the
lead author (AP) and second reviewer ( JW) to identify
studies that potentially meet the inclusion criteria out-
lined above. The second reviewer ( JW) will review titles
and abstract independently and list studies to be
included and those to exclude. Any disagreement
between two reviewers over the eligibility of particular
studies will be resolved through further discussion and/
or with third reviewer (IM) involvement.
A standardised, prepiloted form will be used to extract
data from the included studies for assessment of study
quality and evidence synthesis. Extracted information
will include: study design; study population and partici-
pant demographics and baseline characteristics; details
of the intervention and control conditions; study meth-
odology; recruitment and study completion rates; out-
comes and times of measurement; information for
assessment of the risk of bias. The lead reviewer (AP)
will extract the data and any ambiguity/questions will be
discussed with second ( JW) and/or third (IM) reviewer.
Missing data will be requested from study authors and/
or manufacturers.
Study quality will be assessed using Cochrane colla-
boration’s risk of bias tool and publication bias by visual
inspection of funnel plots.19
Narrative qualitative evidence synthesis will be pro-
vided on aggregate level on study outcome for their
primary and secondary outcome. Qualitative reporting
of evidence will be based on 21 items listed on standards
for reporting qualitative research (SRQR).20 Total
Figure 1 PRISMA flow diagram of identification, screening, eligibility and inclusion studies.
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number of patients in the study, study quality, risk of bias
and effect size will be detailed on qualitative evidence
summary.
Meta-analysis
It is authors’ intention to undertake quantitative
meta-analysis. If study data and sample size are sufficient
meta-analysis will be performed. Statistical significance
will be set at 0.05 with p value <0.05 considered statistic-
ally significant. The primary effect size will be relative
risk presented with 95% CI. The analysis will be based
on intention-to-treat where data available. Study hetero-
geneity will be measured using I2-statistic considering
values of 50% or higher to reflect considerable hetero-
geneity which will be investigated.
Sensitivity analysis
If sufficient number of studies (eg at least one RCT on
each side of the parameter) and sample size are avail-
able, sensitivity analysis will be carried out on manic
versus depressive symptoms and monotherapy versus
adjunctive therapy or different antipsychotic.
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